Eventide Asset Management - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 139 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$30,298,577
+286.7%
1,018,782
+134.3%
0.54%
+312.9%
Q2 2023$7,834,519
+12.2%
434,7680.0%0.13%
+3.1%
Q1 2023$6,982,374
+89.5%
434,768
+80.3%
0.13%
+132.7%
Q1 2021$3,685,000
-34.7%
241,140
-39.7%
0.06%
-36.8%
Q4 2020$5,644,000
-73.3%
400,000
-70.3%
0.09%
-78.9%
Q3 2020$21,107,000
-10.6%
1,347,0000.0%0.41%
-19.5%
Q2 2020$23,599,000
+69.5%
1,347,000
+42.2%
0.51%
+13.7%
Q1 2020$13,921,000
-41.4%
947,0000.0%0.45%
-32.6%
Q4 2019$23,760,000
+66.8%
947,0000.0%0.67%
+42.0%
Q3 2019$14,243,000
-29.1%
947,000
+17.8%
0.47%
-22.9%
Q2 2019$20,096,000
+129.9%
803,839
+109.3%
0.61%
+103.0%
Q1 2019$8,740,000
+136.5%
384,000
+211.6%
0.30%
+83.5%
Q4 2018$3,696,000
+4.7%
123,2250.0%0.16%
+26.2%
Q3 2018$3,530,000123,2250.13%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2023
NameSharesValueWeighting ↓
Vivo Capital, LLC 3,375,169$84,379,0007.91%
RA Capital Management 1,875,209$46,880,0002.52%
Perceptive Advisors 2,587,953$64,698,0001.48%
New Leaf Venture Partners, L.L.C. 167,700$4,193,0001.12%
Orbimed Advisors 2,039,282$50,982,0000.79%
Eventide Asset Management 803,839$20,096,0000.61%
Novo Holdings A/S 135,009$3,375,0000.47%
Opaleye Management Inc. 36,000$900,0000.27%
ADAGE CAPITAL PARTNERS GP, L.L.C. 490,000$12,250,0000.03%
Baker Brothers Advisors 132,985$3,325,0000.02%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders